ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

Jacques Fellay, Alexander J. Thompson, Dongliang Ge, Curtis E. Gumbs, Thomas J. Urban, Kevin V. Shianna, Latasha D. Little, Ping Qiu, Arthur H. Bertelsen, Mark Watson, Amelia Warner, Andrew J. Muir, Clifford Brass, Janice Albrecht, Mark Sulkowski, John G. McHutchison, David B. Goldstein

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.

Original languageEnglish (US)
Pages (from-to)405-408
Number of pages4
JournalNature
Volume464
Issue number7287
DOIs
StatePublished - Mar 18 2010

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C'. Together they form a unique fingerprint.

Cite this